BioCentury
ARTICLE | Company News

AmpliPhi BioSciences, Intrexon deal

April 22, 2013 7:00 AM UTC

AmpliPhi and Intrexon partnered to develop bacteriophage-containing therapeutics to treat bacterial infections associated with acute and chronic wounds, acute and chronic Pseudomonas aeruginosa lung infections and Clostridium difficile infections. Under the deal, AmpliPhi will receive exclusive, worldwide rights to use Intrexon's synthetic biology technologies to design and produce bacteriophages for AmpliPhi's bacteriophage programs. Intrexon will receive 24 million AmpliPhi common shares, which are valued at about $2.9 million based on AmpliPhi's close of $0.12 on April 15, before the deal was announced. Intrexon is eligible to receive milestones plus royalties. Intrexon declined to disclose details, while AmpliPhi could not be reached. ...